Tests platelet rich plasma injections against alprostadil for erectile dysfunction
Compares platelet rich plasma injections with alprostadil in men with erectile dysfunction.
Plain-language title generated from the registry record
Registry title: Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)
Key facts
- Where
- Bari, ItalySee the site
Where in Italy
- Policlinico di Bari - Azienda Ospedaliero Universitaria Consorziale PoliclinicoBari, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Trial code
- NCT06768177
- Record updated
- 2 October 2025
- Original description
Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.Read full original descriptionShow less
Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)
Patients are randomized into 2 groups (A and B), subsequently group A is subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP while group B is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. After 4 (four) weeks the groups will be crossed, so group A will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group B will be subjected to a cycle of 6 weekly injections of 3 ml of autologous PRP.
Inclusion: Moderate to severe erectile dysfunction (IIEF-5 score below 17); Patients previously treated with first- and second-line therapies for ED; Patients who have undergone radical pelvic surgery with nerve sparing; Good pharmacological blood pressure control; Well-controlled diabetes on medication; Current or former smokers; Good renal function even with the use of medications; Well-controlled hypertriglyceridemia and/or hypercholesterolemia even with the use of medications; BMI less than or equal to 35; Normal levels of FSH, LH, PRL, Total Testosterone, and TSH.
Exclusion: Patients on antidepressant, anxiolytic, sedative, or antipsychotic medications; Consumers of more than 500 g of alcohol per day; BMI greater than 35; Altered levels of FSH, LH, PRL, Total Testosterone, and TSH.